Synthesis of 4(2H-1,2,3-triazol-2-yl)pyrimidines

4-(2H-1,2,3-triazol-2-yl)pyrimidines were synthesized. The title compounds tested for analgesic and antiinflammatory activity did not show any significant activity.     

Potential antihypertensives. Synthesis of 6-substituted-N-(4H-1,2,4-triazol-4-yl)-3-pyridazinamines and 3-substituted-6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)pyridazines

A series of 6-substituted-N-(4H-1,2,4-triazol-4-yl)-3-pyridazinamines [(II), Scheme 1] and 3-substituted-6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl) pyridazines [(XII), Scheme 3-5] were synthesized. The compounds were evaluated for their oral antihypertensive activity in rats (SHR) and only some compounds of structure (XII) induced a moderate decrease in systolic blood pressure.     

Synthesis of (Z)-1,3-diaryl-2-(4-aryl-1H-1,2,3-triazol-1-yl)prop-2-en-1-ones and their antibacterial studies

The cyclization of 1,3-diaryl-2-azido-2-propen-1-ones with various alkynes in the presence of a catalytic amount of copper sulfate–sodium ascorbate in DMSO–water mixture under microwave irradiation led to the formation of (Z)-1,3-diaryl-2-(4-substituted-1H-1,2,3-triazol-1-yl)prop-2-en-1-ones. The structure and stereochemistry of the products have been elucidated by spectroscopic and single crystal X-ray analyses. All the newly synthesized compounds have been tested for their antibacterial activity against four strains of bacteria and found to have moderate to good inhibition.     

4-[1-烷基-5-氧代-1H-1,2,4-三唑-4(5H)-基]-苯甲酸的合成

目的制备用于全合成卡泊芬净类环六脂肽抗真菌剂的关键脂肪酸侧链4-[1-烷基5-氧代-1H-1,2,4-三唑4（5H）-基]-苯甲酸（5）。方法以对氨基苯甲酸（1）为起始原料,经氨基苯氧羰酰化、肼解、甲脒环合及N-烃化4步反应制备目标化合物。结果以42．9％～46．2％的总收率成功合成了目标化合物5a～5n,其结构经电喷雾质谱（ESI—MS）和氢谱（^1HNMR）确证;所有目标化合物均为首次报道。结论该合成路线具有操作简便及收率高等优点,适合工业化生产。     

叔丁基三唑衍生物的合成及抗真菌活性研究

目的研究具有叔丁基结构的三唑醇类化合物的抗真菌活性以及各种4-(4-烷氧基苯基)哌嗪侧链的引入对抗真菌活性的影响.方法以一氯频那酮、三氮唑为原料,经多步反应合成目标化合物,化合物结构经IR、1H-NMR谱确证;选择8种真菌为实验菌株,按国际标准抗真菌敏感性实验方法测定其体外抗真菌活性.结果设计合成了10个新化合物.10个目标化合物对8种真菌均具有一定的抑制活性,其中,有4个化合物对白色念珠菌的MIC80值小于或等于0.125 mg·L-1,是氟康唑的4倍以上,与伊曲康唑相当.结论可以通过引入更多的疏水基团设计三唑醇类化合物,立体化学因素对该类化合物的体外抑菌活性有较大影响.     

含哌嗪环的三唑醇类化合物的合成及体外抗真菌活性

目的设计合成含哌嗪环侧链的三唑醇类化合物并研究其体外抗真菌活性。方法以2-氯-2′,4′-二氟苯乙酮为起始原料经多步反应合成目标化合物，化合物结构经IR、^1H-NMR谱确证；选择8种真菌为实验菌株，按国际标准抗真菌敏感性实验方法测定体外抑菌活性。结果设计合成了11个新化合物。所有目标化合物对8种真菌均具有一定的抑制作用。结论多个目标化合物的抗真菌活性明显高于阳性对照药氟康唑，其中化合物11具有广谱、高活性的优点，其体外抗真菌活性与对照药伊曲康唑相当，有进一步研究开发的价值。     

1-(1H-1,2,4-三唑-1-基)-2-(2,4-二氟苯基)-3-[(4-取代)-哌嗪-1-基]-2-丙醇的合成及其抗真菌活性

目的研究不同取代哌嗪侧链的引入对三唑醇类化合物抗真菌活性的影响.方法设计合成了13个三唑醇类新化合物;选择8种真菌为实验菌株,进行体外抑菌活性测试.结果目标化合物对8种真菌特别是深部真菌均有一定的抑制活性,其中有8个化合物对白色念珠菌的MIC80值小于或等于0.125μg/mL,是氟康唑活性的4倍以上,与酮康唑活性相当.结论脂水分配系数和立体化学因素的改变对该类化合物体外抑菌活性有较大影响.     

Synthesis and anticonvulsant activity evaluation of 8-alkoxy-5-(4H-1,2,4-triazol-4-yl)quinoline derivatives

Two series of 8-alkoxy-5-(4H-1,2,4-triazol-4-yl)quinolines and 8-alkoxy-5-(2H-1,2,4-triazol-3-one-4-yl)quinolines were synthesized. The anticonvulsant activity of these compounds was evaluated with maximal electroshock seizure test and rotarod test. Among the synthesized compounds, 8-octoxy-5-(4H-1,2,4-triazol-4-yl)quinoline (4g) was the most active compound with ED₅₀ of 8.80 mg/kg, TD₅₀ of 176.03 mg/kg and protective index of 20.0. Its neurotoxicity was lower than all other synthesized compounds and also markedly lower than that of the reference drug carbamazepine. In addition, the potency of compound 4g against seizures induced by pentylenetetrazole, 3-mercaptopropionic acid, and bicuculline suggested its broad spectrum activity, and the mechanisms of action including inhibition of voltage-gated ion channels and modulation of GABAergic activity might involve in its anticonvulsant activity.     

Synthesis, cytotoxicity testing, and structure-activity relationships of novel 6-chloro-7-(4-phenylimino-4H-3,1-benzoxazin-2-yl)-3-(substituted)-1,4,2-benzodithiazine 1,1-dioxides

A new series of 16 6-chloro-1,1-dioxo-7-{4-[(4-R(1)-phenyl)imino]-4H-3,1-benzoxazin-2-yl}-3-(substituted amino)-1,4,2-benzodithiazines 7-22 was prepared in order to evaluate the cytotoxic activity against six human cancer cell lines. The structures of the new compounds were confirmed by IR, (1)H-, and (13)C-NMR, elemental analysis and in the cases of 11 and 31 by X-ray crystal structure analysis. This analysis showed that contrary to our earlier report the structures contain a benzoxazine ring instead of the proposed quinazolinone ring. The bioassay indicated that the benzodithiazine derivatives 7-22 possess cancer cell growth-inhibitory properties. Some compounds showed a high level of selectivity for certain cell lines. The most active compounds 11, 12, 16, 19, 21, and 22 exhibited potency higher or comparable to cisplatin. The compounds were particularly effective in LCLC-103H and MCF-7 cell lines with IC(50) values of 0.49-1.60 μM. Quantitative structure activity relationships (QSAR) revealed that a chloro substituent R(1) in the phenyl ring as well as the shape of the substituted amino group at R(2) (e.g., unsaturation is beneficial) are important for potency.     

Synthesis of new 1-(amino)-3-[(1,5-diphenyl-1H-1,2,4-triazol-3-yl) oxy] propan-2-ol and 1-[(1,5-diphenyl- 1H- 1,2,4-triazol-3-yl) oxy]-3-(4-arylpiperazin-1-yl) propan-2-ol derivatives with an expected beta-adrenolytic activity

3-(Oxiran-2-ylmethoxy)-l ,5-diphenyl-lH-1,2,4-triazole [I] was obtained in the reaction of 1,5-di-phenyl-IH-1,2,4-triazol-3-ol with 2-(chloromethyl) oxirane. Then I was converted into the corresponding aminoalkanol derivatives of 1,5-diphenyl-IH-1,2,4-triazol-3-ol, IIa,b -VIIa,b. Molecular structure of I was confirmed by an X- ray structure analysis. The receptor affinities for IVa, VIIa were determined.     

Synthesis and characterization of 2-(4-((1-alkyl or aryl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)naphtho[1,2-d]oxazoles for protein tyrosine phosphatase 1B inhibitory activity

2-(4-((1-Alkyl/aryl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)naphtho[1,2-d] were prepared and evaluated as protein tyrosine phosphatase 1B (PTP1B) inhibitors. In this study, two new compounds with potent PTP1B inhibitory activity were identified.     

Synthesis,characterization and biological evaluation of 7-substituted- 4-((1-aryl-1H-1,2,3-triazol-4-yl) methyl)-2H-benzo[b][1,4]oxazin- 3(4H)-ones as anticancer agents

A series of novel 1,2,3-triazole-2H-benzo[b][1,4]oxazin-3(4H)-ones (4a–4k and 5a–5g) were designed, synthesized and screened for their anticancer activity against MCF-7 (breast) and HeLa (cervical) cell lines using [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay. Among all the tested compounds, 5b and 5c exhibited good cytotoxic activity against two cancer cell lines with IC₅₀ values nearer to the standard drug, cisplatin. The most active compounds 5b and 5c were further evaluated for their in vivo anticancer activity against Ehrlich Ascites Carcinoma-bearing mice and compound 5c found to possess potential cytotoxic activity as compared with the reference drug cisplatin. Molecular docking studies were also carried out to complement the experimental results.     

3-取代三唑醇类化合物的合成及抗真菌活性

目的设计合成1-(1H-1,2,4-三唑-1-基)-2-(2,4-二氟苯基)-3-烷氧基苯基哌嗪-2-丙醇和1-(1H-1,2,4-三唑-1-基)-2-(2,4-二氟苯基)-3-取代硫醚-2-丙醇化合物,并进行体外抗真菌活性测试.方法以间二氟苯为起始原料,经多步反应,得到中间体环氧化物甲烷磺酸盐,再与各种烷氧基苯基哌嗪和取代硫醇开环得到目标化合物,按国际标准抗真菌敏感性实验方法测定其体外抗真菌活性.结果共合成12个(其中11个为新化合物)目标化合物,经元素分析,1H-NMR和IR确证结构,其中4个化合物的抗真菌活性强于对照品氟康唑和酮康唑.结论含烷氧苯基哌嗪侧链的三唑醇类化合物具有较强的抗真菌活性.     

4-(4-烷氧基苄基/苯乙基)-2H-1,2,4-三唑-3(4H)-酮类化合物的合成及其抗惊厥活性

目的设计合成一系列4-(4-烷氧基苄基/苯乙基)-2H-1,2,4-三唑-3(4H)-酮类化合物,并评价其抗惊厥活性和神经毒性。方法以对羟基苄胺和对羟基苯乙胺为起始原料,通过氨基保护、羟基烷基化、氨基脱保护以及氨基成三唑酮环反应合成目标化合物。采用最大电惊厥实验(MES)评价化合物的抗惊厥活性,采用旋转棒法测定其神经毒性。结果与结论合成了26个未见文献报道的新化合物,其结构经IR、1H-NMR、13C-NMR和EI-MS谱确证。活性实验结果表明,所有化合物在不同剂量下都显示出抗惊厥活性。其中,4-[4-(3-氟苄氧基)苯乙基]-2H-1,2,4-三唑-3(4H)-酮(9f)的活性最强,其半数有效量ED50值为19.5 mg·kg-1,保护指数(PI)为5.1。该化合物的PI值高于阳性对照药丙戊酸钠,低于卡马西平。     

Synthesis of 6-(3-substituted-4H-1,2,4-triazol-4-yl)-2-phenylbenzo[d]oxazoles as potential anticonvulsant agents

A series of 6-(3-substituted-4H-1,2,4-triazol-4-yl)-2-phenylbenzo[d]oxazoles was synthesized. The anticonvulsant effect and neurotoxicity of the compounds were calculated with maximal electroshock (MES) test, subcutaneous pentylenetetrazole (Sc-PTZ), and rotarod tests in intraperitoneally injected mice. Among the synthesized compounds, compound 2-phenyl-6-(4H-1,2,4-triazol-4-yl)benzo[d]oxazole (3a) could be considered the potentially most useful and safe therapeutic compound, with ED₅₀ = 29.6 mg/kg, TD₅₀ = 285 mg/kg, and PI = 9.7. Its neurotoxicity was the lowest of all the synthesized compounds and was also markedly lower than that of the reference drug carbamazepine with PI value of 6.4.     

半乳凝素-3潜在抑制剂—1-O-烯丙基-4-O-{3-脱氧-3-[4-苄胺羰基-1H-（1，2，3）三氮唑-1-基]-β-D-吡喃半乳糖基}-2-脱氧-2-乙酰氨基-β-D-吡喃葡萄糖的合成

以乳糖为原料设计合成了半乳凝素-3的潜在抑制剂—1-O-烯丙基-4-O-{3-脱氧-3-[4-苄胺羰基-1H-（1,2,3）三氮唑-1-基]-β-D-吡喃半乳糖基}-2-脱氧-2-乙酰氨基-β-D-吡喃葡萄糖。乳糖2-位的改造采用了叠氮-碘糖基化法,在乙酰氨基引入的同时立体选择性地构建了β-氨基乳糖苷;通过两次构型翻转在3′-位引入叠氮基,然后采用Click反应构建出三氮唑羧基,再与苄胺反应便得到目标物。对乳糖的上述改造旨在提高其对半乳凝素-3的亲和活性。     

Redifferentiation of human hepatoma cell induced by 6-(p-chlorophenyl)-3-[1-(p-chlorophenyl)-5-methyl-1 H-1,2,3-triazol-4-yl]-s-triazolo[3,4-b]-1,3,4-thiadiazole (TDZ)

6-(p-Chlorophenyl)-3-[1-(p-chlorophenyl)-5-methyl-1 H-1,2,3-triazol-4-yl]-s-triazolo[3,4-b]-1,3,4-thiadiazole (TDZ) is a derivative of various substituted s-triazolo[3,4-b]-1,3,4-thiadiazoles, which are associated with diverse pharmacological activities. However, the antitumor activity of TDZ is not well understood. To evaluate its role on tumor cell lines, we have examined the effect of TDZ on two tumor lines: human hepatoma cell (SMMC-7721) in vitro and Sarcoma180 tumor (S180) in vivo. The cytotoxicity of TDZ on human hepatoma cells was assessed using the MTT assay. The inhibition on tumor growth was evaluated by means of trypan blue exclusion test in vitro, and using a Sarcoma180 tumor (S180) animal model in vivo. A scanning electronic microscope was used to discover the morphological changes on cell surface, cell electrophoresis was employed to determine the changes of cell surface negative charges, and alpha-fetoprotein was applied as a biomarker of hepatoma. The effect of TDZ on DNA synthesis was determined by a [3H]-thymidine incorporation assay, and cell cycle distribution by flow cytometry. The IC50 value of TDZ on SMMC-7721 cells was 52.9 microg/ml (48 h). However, TDZ could inhibit the growth of SMMC-7721 cells at concentrations far lower than the IC50 value. Treated with the same low concentrations of TDZ, microvilli on the surface of SMMC-7721 cells decreased obviously, electrophoresis rate of cells reduced from 2.14 microm ms(-1) x V(-1) x cm(-1) of control to 1.54 and 1.56 microm x s(-1) x V-1 x cm(-1), the content of AFP dropped from 205.14 +/- 6.41 ng x mg(-1) Pr to 115.68 +/- 3.47 and 78.57 +/- 2.35 ng mg(-1) Pr, and the DNA replication was inhibited by 26.8% and 45.2%. These results indicated that TDZ may inhibit proliferation of cancer cells by reversing SMMC-7721 cells malignant phenotypic characteristics and inducing redifferentiation. Flow cytometry showed that TDZ-treated cells resulted in a higher proportion of cells in S phase compared with untreated cells, and only when the concentration reached 64 microg/ml, the apoptosis could happen at the rate of 4.2%. Detection of the inhibition of Sarcoma 180 tumor growth in vivo showed that TDZ reduced the tumor weight and 69.08% of the growth was inhibited. TDZ could inhibit the proliferation of tumors in vitro and in vivo; the possible antitumor mechanism might be inducing redifferentiation at a lower dosage on vitro.     

Synthesis and antimicrobial evaluation of some 3-(substituted phenacyl)-5-[4'-(4H-4-oxo-1-benzopyran-2-yl)-benzylidene]-2,4- thiazolidinediones.

Synthesis and in vitro antimicrobial activity of some 3-(substituted phenacyl)-5-[4'(4H-4-oxo-1-benzopyran-2-yl)-benzylidene]-2-4- thiazolidinedione derivatives are described. These products were synthesized by the Knoevenagel reaction from 4'-flavone carboxaldehyde and 3-substituted phenacyl-2,4-thiazolidinediones.     

Synthesis and antiviral activity of 1-[1,5-dialkyl-1H-1,2,4-triazol-3-yl)methyl]thymines.

Cycloaddition of the intermediates 2 with 1-(cyanomethyl)-thymine 3 furnished the 1,2,4-triazolium salts 4, which rearranged spontaneously to the protonated salts 5. Hydrolysis of 5, in situ, afforded the title compounds 6. Compounds 6a-c were screened against HIV-1 (IIIB), HIV-2 (ROD), and human cytomegalovirus (HMCV) and showed poor or no activity, respectively.     

Orally active cephalosporins. I. Synthesis and structure-activity relationships of 7 beta-[2-(R)-amino-2-phenylacetamido]-3-(1H- 1,2,3-triazol-4-yl)alkylthiomethyl-3-cephem-4-carboxylic acid and related compounds]

The synthesis, antibacterial activity and oral absorbability of 7 beta-[2-(R)-amino-2-phenylacetamido]-3-(1H-1H-1,2,3-triazol- 4-yl)methylthiomethyl-3-cephem-4-carboxylic acid (1a) and related compounds (1b-p and 2) are described. The replacement of 1,2,3-triazole at the C-3 position of 1a with other heteroaromatics such as 1,2,4-triazole, imidazole and so on decreased its oral absorbability in mice (1b-j). The oral absorbability was also influenced by the spacer length between C-3 of cephem nucleus and C-4 of 1,2,3-triazole. The quantitative relationship between the bioavailability and the spacer length of cephalosporins (1a and 1k-p) is discussed. These results suggest that 1,2,3-triazole in the side chain at the C-3 position of cephems plays an important role in good oral absorption through its interaction with the transport system of small intestine.